NHS England to Cover Lynparza Earlier in Advanced OC Treatment

NHS England to Cover Lynparza Earlier in Advanced OC Treatment
Maintenance treatment with Lynparza (olaparib) is now recommended after response to the first round of platinum-based chemotherapy in women with advanced ovarian cancer on England’s National Health Service (NHS). The decision by the National Institute for Health and Care Excellence (NICE) means that patients with BRCA mutations may receive Lynparza earlier, as three different chemotherapies were required under the previous recommendation. Similar decisions were announced in the United States, European Union, and Japan. Treatment with Lynparza will typically last up to two years, but longer courses are possible if the cancer is detected and doctors think it may be beneficial. Approximately 700 patients in the United Kingdom are expected to benefit from Lynparza yearly, according to NICE. Rose Gray, Cancer Research UK’s policy manager, said this was “fantastic news” that “will offer new hope” to patients. “Patients and clinicians told NICE there is a real need for new treatments for this cancer type, and that using [Lynparza] earlier in patients’ treatment could mean the drug offers greater benefit,” she said. This broader availability will be paid for through the Cancer Drugs Fund (CDF), and covers patients with advanced ovarian cancer and gynecological cancers of the fallopian tube and the peritoneum — the layer lining the abdominal cavity. Treatments funded by the CDF in England are usually funded by the NHS in Wales and Northern Ireland. Coverage in Scotland is decided separately by the Scottish Medicines Consortium. Lynparza, a PARP enzyme inhibitor, is intended to prevent cancer cells from repairing their DNA errors, leading to their death. Its efficacy is especially high in cancers with mutations in DNA-repairing gene
Subscribe or to access all post and page content.